Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margarida Alves

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Rheumatology (Oxford, England)|September 16, 2022
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trialChristopher P Denton, Nicole S Goh, Stephen M Humphries, et al.
Respiratory Investigation|November 23, 2020
Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trialArata Azuma, Lorinda Chung, Digambar Behera, et al.
RMD Open|July 15, 2026
Expert viewpoint on endpoints in systemic sclerosis: current and future outlookAnna-Maria Hoffmann-Vold, Oliver Distler, Francesco Del Galdo, et al.
Rheumatology (Oxford, England)|February 12, 2022
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trialElizabeth R Volkmann, Michael Kreuter, Anna M Hoffmann-Vold, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Rheumatology (Oxford, England)|June 3, 2025
Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR studyVincent Sobanski, Jeska de Vries-Bouwstra, Anna-Maria Hoffmann-Vold, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 13, 2021
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness ScoreMasataka Kuwana, Yannick Allanore, Christopher P Denton, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
Ciencia & Saude Coletiva|April 12, 2023
[The use of dental services in the past year in the brazilian population: a systematic review with meta-analysis]Cinthia Nara Gadelha Teixeira, Sângela Maria da Silva Pereira, Juliana Balbinot Hilgert, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Rheumatology (Oxford, England)|September 16, 2022
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trialChristopher P Denton, Nicole S Goh, Stephen M Humphries, et al.
Respiratory Investigation|November 23, 2020
Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trialArata Azuma, Lorinda Chung, Digambar Behera, et al.
RMD Open|July 15, 2026
Expert viewpoint on endpoints in systemic sclerosis: current and future outlookAnna-Maria Hoffmann-Vold, Oliver Distler, Francesco Del Galdo, et al.
Rheumatology (Oxford, England)|February 12, 2022
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trialElizabeth R Volkmann, Michael Kreuter, Anna M Hoffmann-Vold, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Rheumatology (Oxford, England)|June 3, 2025
Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR studyVincent Sobanski, Jeska de Vries-Bouwstra, Anna-Maria Hoffmann-Vold, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 13, 2021
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness ScoreMasataka Kuwana, Yannick Allanore, Christopher P Denton, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
Ciencia & Saude Coletiva|April 12, 2023
[The use of dental services in the past year in the brazilian population: a systematic review with meta-analysis]Cinthia Nara Gadelha Teixeira, Sângela Maria da Silva Pereira, Juliana Balbinot Hilgert, et al.
Pageof 6